EIN Presswire: Merck Press Releases

Growing Popularity of Herbalife 'Extravaganza' Reflects Strong Prospects for Asian Nutrition Market

Thu, 24 May 2012 07:41:00 +0000

Growing Popularity of Herbalife 'Extravaganza' Reflects Strong Prospects for Asian Nutrition Market

PR Newswire

24,000 delegates attended, SGD 213,410 raised for charity

SINGAPORE, May 24, 2012 /PRNewswire-Asia/ -- Catering to the increasingly health-conscious Asian consumers, Herbalife has achieved significant success in the region with an ever-expanding network of independent distributors. This is reflected by the growing popularity of the Herbalife Asia Pacific 'Extravaganza', a gathering of a record 24,000 of its independent distributors from across Asia Pacific to discuss the latest nutrition trends, product training and business-building initiatives at the Singapore EXPO. This weekend's event saw an increase of 41%* in the number of delegates since 2010, demonstrating the huge rise in interest around affordable nutrition supplements that help with the weight management and the fitness needs of Asian consumers.

(Photo: http://www.prnasia.com/sa/2012/05/24/20120524132621613714.html )

"Herbalife emphasizes the personal development of our growing pool of independent distributors in the region and has invested in training forums, which we organize throughout the year. The Extravaganza is a key platform for Herbalife to arm our distributors with training in our products, business and marketing strategies. It is a forum for exchanging success stories and contribute to building an overall business model for them to succeed in their business," said William M. Rahn, managing director, Herbalife Asia Pacific.

The Herbalife Extravaganza 2012 was a major milestone for the local MICE industry in Singapore. Occupying 400,000 sqft of space at Singapore EXPO Convention & Exhibition Centre and all the rooms at its new convention wing, MAX Atria, the event required careful logistical planning and impeccable execution.

Aloysius Arlando, chief executive officer of Singex Venues Pte Ltd., the managing company for EXPO said, "Herbalife Extravaganza has always added much vibrancy to EXPO whenever it came round, and this year was no exception. While EXPO is no stranger to hosting large-scale international events, it was the first time EXPO had hosted a 24,000-delegate Extravaganza. Through meticulous planning and efficient deployment of resources, our experienced Event Services and Operations teams worked closely with Herbalife to ensure that every event component, from registration to conference and plenary session, proceeded with clockwork precision to provide a smooth and memorable visitor experience for delegates. We were also delighted to introduce our Green Mark Platinum-certified convention wing, MAX Atria, to our regional visitors. We certainly look forward to the next edition in Singapore with even greater numbers!"

As part of Herbalife's commitment to help improve the lives of vulnerable children through its Casa Herbalife programs, the Extravaganza also helped raise funds for its 16 Casa Herbalife programs in the region. Combining this with the efforts by local distributors at Herbalife Singapore's 9th anniversary recently, a total of SGD 213,410 was raised and will be donated to the Singapore Children's Society and other charities throughout the region.

About Herbalife

Herbalife Ltd.( http://www.herbalife.com/global ) (NYSE:HLF) is a global nutrition company that sells weight-management, nutrition, and personal care products intended to support a healthy lifestyle. Herbalife products are sold in 81 countries through a network of independent distributors. The company supports the Herbalife Family Foundation( http://www.herbalifefamilyfoundation.org ) and its Casa Herbalife program to help bring good nutrition to children. Herbalife's website contains a significant amount of information about Herbalife, including financial and other information for investors at http://ir.Herbalife.com. The company encourages investors to visit its website from time to time, as information is updated and new information is posted.

*Fast Facts on past Herbalife Extravaganzas held in Singapore

The first Herbalife Asia Pacific Extravaganza in Singapore in 2003 attracted 10,000 participants from 12 countries, while in 2010 there were 17,000 attendees. This year 24,000 participants from 25 countries came together at the Singapore EXPO from 18 May to 20 May.

Media Contact:

Daliea Mohamad-Liauw

dalieal@herbalife.com

D: +852-6119-1690

M: +852-3589-2643

SOURCE　Herbalife

Merck Serono Supports 4th International Thyroid Awareness Week

Thu, 24 May 2012 07:26:00 +0000

Merck Serono Supports 4th International Thyroid Awareness Week

PR Newswire

GENEVA, Switzerland, May 24, 2012 /PRNewswire/ --

Merck Serono, a division of Merck, Darmstadt, Germany, today announced its support of an awareness campaign on thyroid disorders and possible related cardiovascular risks. The campaign is in conjunction with the fourth annual International Thyroid Awareness Week 2012. Merck Serono and its affiliates worldwide will organize educational activities and public information sessions during May 21-27.Merck Serono has conducted research involving both patients and medical doctors to enhance awareness of the underlying reasons behind the low treatment rate of the condition. Finalized results will be communicated in the coming weeks.

The International Thyroid Awareness Week is supported by Merck Serono in cooperation with Thyroid Federation International, European Thyroid Association, Latin American Thyroid Society, American Thyroid Association,ChineseSociety of Endocrinology, Asia,Oceania and Thyroid Association. In 2011, the third International Thyroid Awareness campaign was successfully rolled out in over 40 countries in collaboration with local patient organizations and members of the medical community.

There are numerous diseases and disorders associated with thyroid, which could develop at any age resulting from a variety of causes; e.g. injury, disease or dietary deficiencies. However, in the majority of cases the disease can be traced back to abnormal thyroid growth, thyroid cancer, or goiters and nodules within the thyroid that could lead to hypothyroidism (under-active thyroid) / hyperthyroidism (over-active thyroid).

Although the role of Thyroid is highly significant to all metabolic processes in the body, it is often unnoticed so long as it does not pose any problems. From the components derived from blood (primarily iodine) the thyroid forms two hormones that control the overall human metabolism. A person's well-being is dramatically affected when the thyroid's sensitive metabolism is thrown off balance.

Since one of the targets of thyroid hormones is the heart; any thyroid dysfunction could ultimately impact it. In the presence of hypothyroidism the heart will slow down, whilst in the case of hyperthyroidism it speeds up. Both of these problems can have serious consequences.

Thyroid disorders are some of the most frequently occurring diseases in the world with about 1.6 billion people worldwide at risk^[¹^]. Without treatment thyroid disorders worsen existing heart diseases or could be the cause of new ones.

For further information on thyroid diseases, cardiovascular risks and the role of iodine in thyroid functioning refer to: http://www.thyroidweek.com.

1. United Nations System Standing Committee on Nutrition (SCN) 5th Report on the World Nutrition Situation, Nutrition for improved Development Outcomes - March 2004. URL http://www.unscn.org/layout/modules/resources/files/rwns5.pdf (Accessed October 2010)

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck KGaA. With headquarters in Geneva, Switzerland, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurodegenerative diseases, oncology and rheumatology.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of €10.3 billion in 2011, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit http://www.merckserono.com or http://www.merckgroup.com

HIMSS Analytics Recognises the First Three Hospitals in P.R.China to Achieve Stage 6

Thu, 24 May 2012 05:52:00 +0000

HIMSS Analytics Recognises the First Three Hospitals in P.R.China to Achieve Stage 6

PR Newswire

As of Q4 2011, just 5.2% of more than 5,300 of hospitals tracked by HIMSS Analytics had reached Stage 6 on its Electronic Medical Record Adoption Model (SM) (EMRAM)

CHANGSHA, China, May 24, 2012 /PRNewswire-Asia/ -- HIMSS Analytics announced that Chang An Hospital, Xi'an and Shengjing Hospital, Shenyang and Yantai Yuhuangding Hospital, Shandong have achieved Stage 6 on EMRAM. Chang An Hospital is renowned for its aim to be a leading international hospital with a focus on cancer treatment. Shengjing Hospital is well known in the Northeast of China for its excellent medical technology and disciplines. Built in 1890, Yuhuangding, the largest integrated healthcare center in Yantai, is well regarded for its advanced facilities.

HIMSS Analytics developed the EMR Adoption Model (SM) in 2005 as a methodology for evaluating the progress and impact of electronic medical record systems for hospitals in the HIMSS Analytics(R) Database. Tracking their progress in completing eight stages (0-7), hospitals can review the implementation and utilization of information technology applications with the intent of reaching Stage 7, which represents an advanced electronic patient record environment.

"Chang An Hospital, Shengjing Hospital and Yuhuangding Hospital have proven to be the world leaders in deploying healthcare information technology for the betterment of patient care. We congratulate them for their Stage 6 achievements," said Steven Yeo, General Manager, HIMSS Analytics Asia.

Chang An Hospital, Shengjing Hospital and Yuhuangding Hospital have successfully met the criteria to be one the few hospitals in the world that have successfully deployed this level of healthcare information technology for the betterment of patient care quality and safety. The hospitals have deployed advanced safety features such as computerized physician order entry (CPOE) and on-line physician documentation, both supported by clinical decision support to offer best practice, evidence based clinical guidance to the physicians.

Nursing care is aided by on-line comprehensive nursing documentation supported by the safety of closed loop medication administration (CLMA) where each unit dose medication is verified by a bar code scan before delivery to the patient to ensure accurate medication delivery are achieved. Closed loop medication administration for each unit dose provides a whole new level of patient safety in medication delivery.

"Fundamentally, EMR has been constructed, protected, maintained and used by medical personnel, patients, and medical facilities in a cooperative manner," says Mr. Jingming Wang, President of Chang An Hospital. "Stakeholders of the EMR system should harness the ease of data transmission and sharing through an internet platform, to fulfill total health management of residents throughout their lifetime as well as fulfill regional healthcare collaborations."

"Using the latest information technology to integrate human resource management and aligning it with electronic medical records, the hospital has achieved closed loop medication administration through implementing a complete medical workflow solution with a self-reinforcing feedback loop. This allows us to continually improve medical safety and our medical services levels," said Professor Guo Qi Yong, President of Shengjing Hospital.

"The inauguration of Yuhuangding Hospital as a Stage 6 hospital truly signified the realization of our vision of 'seeking knowledge, benevolence and excellence' and striving to set the hospital as one of the leading facilities in China. We have studied and learnt from our peers, and will continue to improve ourselves to a level that we aspire to be. Hospital HIT development is a long-term project and we have to strive hard and unrelentingly without fail," said Professor Liu Yunxiang, President of Yuhuangding Hospital.

The Stage 6 Award presentation will be held at the CHIMA/HIMSS Analytics EMRAM Workshop in Changsha on 26 May, 2012.

Visit www.himssanalyticsasia.org to learn more about Stage 6 recognition.

Notes to editor:

-- Criteria for Stage 6 hospitals

-- Have made significant executive commitments and investments

to reach this stage.

-- Appear to have a significant advantage over competitors for

patient safety, clinician support, clinician recruitment,

and competitive marketing for both consumers and nurse

recruitment.

-- Have almost fully automated/paperless medical records when

they have implemented their IT applications across most of

the inpatient care settings.

-- Are either starting to evaluate their data for care delivery

process improvements or have already documented significant

improvements in this area.

-- Have made investments that are within reach of most hospitals

and recognize the strategic value of improving patient care

with the EMR.

-- Have begun to create strategic alignments with their medical

staff to effectively utilize information technology to improve

the patient safety environment

-- Are well positioned to provide data to key stakeholders,

such as payers, the government, physicians, consumers, and

employers, to support electronic health record environments

and health information exchanges.

-- Stage 6 hospitals also have achieved a significant advancement

in their IT capabilities that positions them to successfully

address many of the current industry transformations, such as

exchange of health information, claims attachments that enable

pay for quality, and government quality reporting programs.

About HIMSS Analytics Asia

HIMSS Analytics is a wholly owned not-for-profit subsidiary of the Healthcare Information and Management Systems Society (HIMSS). The company collects and analyzes healthcare data related to IT processes and environments, products, IS department composition and costs, IS department management metrics, healthcare trends and purchase-related decisions. HIMSS Analytics delivers high quality data and analytical expertise to healthcare delivery organizations, healthcare IT companies, state governments, financial companies, pharmaceutical companies, and consulting firms. For more information, please visit www.himssanalyticsasia.org.

SOURCE　HIMSS Analytics Asia

First-In-Country TomoTherapy(R) Systems Operate in Thailand and the Philippines

Thu, 24 May 2012 03:55:00 +0000

First-In-Country TomoTherapy(R) Systems Operate in Thailand and the Philippines

PR Newswire

TomoTherapy System Provides Patients Accurate and High Quality Individualized Treatments

SUNNYVALE, Calif., May 24, 2012 /PRNewswire-Asia/ -- Accuray Incorporated( http://www.accuray.com ) (Nasdaq: ARAY), the premier radiation oncology company, announced today that Maharaj Nakorn Chiang Mai Hospital ('Chiangmai University Hospital') in Chiang Mai, Thailand and Makati Medical Center ('MakatiMed') in Manila, Philippines have begun treating patients with the TomoTherapy(R) System( http://accuray.com/products/tomotherapy-system ), a fully-integrated, 3D image-guided intensity modulated radiation therapy (IG-IMRT). The TomoTherapy System allows Chiangmai University Hospital and MakatiMed to offer patients a non-invasive, personalized option for the treatment of tumors throughout the body, making these two hospitals the first-in-country installed sites of the TomoTherapy System in the ASEAN region. Both hospitals commenced treatment of their first patients in the spring.

"Being one of the most reputable hospitals and the first hospital with TomoTherapy Hi Art System available in Northern Thailand, we are committed to providing patients the best technological innovations for cancer care and the highest quality of healthcare services," said Dr. Somsak, Wanwilairat, Ph. D, Chief Physicist, Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai University. "We recognize that the IMRT for treating a wide range of cancers is a viable option to meet the needs of a diverse patient population across 17 provinces in the northern region and foreign patients with shortened room treatment time."

"TomoTherapy perfectly combines image-guided technology and radiation treatment delivery capabilities. We can address almost all types of cancers, from irregularly shaped tumors to long treatment fields like multiple tumors along the spine or in the brain," said Dr. Kathleen Baldivia, head of MakatiMed's Radiation Oncology Section. "With the radiation beam further subdivided into beamlets, TomoTherapy allows doctors to give varying doses across one treatment area, thus resulting in reduced toxicity and improving patients' quality of life."

The TomoTherapy System combines a revolutionary design, with industry-leading treatment precision and daily image guidance for true treatment accuracy. The TomoTherapy System is a fully-integrated, 3D image-guided intensity modulated radiation therapy (IG-IMRT) system. Through daily CT imaging, the TomoTherapy System allows clinicians to give each patient accurate and high quality individualized treatments specifically tailored to their needs. Unique helical delivery means a broader range of tumors can be treated, expanding options for more patients.

"We are pleased to extend the benefits of TomoTherapy treatment and daily image guidance to patients in Thailand, The Philippines and surrounding regions," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "As leading hospitals in the ASEAN region Chiangmai University Hospital's and MakatiMed's installations mark a significant milestone for Accuray as we look forward to expanding our global presence and improving access to treatment solutions that improve patient outcomes and care."

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to reputation, the anticipated benefits of the TomoTherapy System, quality of care, the expansion of our global presence, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the Company's reports Form 10-Q for the first, second and third quarters of fiscal 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

SOURCE　Accuray Incorporated

Philips launched Ambient Experience in China

Wed, 23 May 2012 23:00:00 +0000

Philips launched Ambient Experience in China

PR Newswire

-- People Focused, Clinical Environment Optimized

HEFEI, China, May 24, 2012 /PRNewswire-Asia/ -- On May 24, 2012, the “People Focused, Clinical Environment Optimized” seminar was held in the Anhui Provincial Children’s Hospital by Philips Healthcare. Delivering technologies that allow greater control of the healthcare experience, Philips Healthcare conceived Ambient Experience on the premise of providing a positive environment for patients and care providers.

(Photo: http://www.prnasia.com/sa/2012/05/23/20120523145520854413.html )

(Photo: http://www.prnasia.com/sa/2012/05/23/20120523145647622807.html )

Ambient Experience integrates architecture, design and enabling technologies such as dynamic lighting video projections and sound, to allow patients to personalize their environment and surround themselves in a relaxing atmosphere. This innovative, people-focused solution enables patients to select room themes and sounds, empowering them to be involved in their own care. Concurrently, designers take special care to address the needs of the clinical staff to make the workplace efficient and pleasant.

While improving patients’ satisfaction, Philips ‘Ambient Experience’ also increases hospitals’ workflow efficiency and staff’s working comfort. “We choose Philips AE because we share highly identical ‘People Focused’ concept. We look forward to seeing our children patients overcome their fears of traditional hospitals and actively follow our instructions on diagnosis and treatment. Meanwhile, I also expect that the application of Philips AE will create a better working environment for our staff, and always remind myself that it is our bounden duty to care for patients,” said Jin Yulian, President of Anhui Provincial Children’s Hospital, an early user of this people focused solution in China.

“Philips has constantly carried out scenario extensions and technical upgrades for ‘Ambient Experience’ in recent years. At the same time, we also plan to make the ‘Ambient Experience’ more suitable for local healthcare in accordance with differentiated needs in different markets. With global resource advantages and local market operations, we will continue to promote more extensive application of AE in China and make ‘people focused’ healthcare benefit the general public,” said Desmond Thio, President of Philips Healthcare Greater China.

More than 300 hospitals globally have installed the Philips Ambient Experience in a range of clinical environments, including clinic lobby and waiting areas, MR, CT, mammography, interventional cardiology (catheterization and EP ) lab suites, PET/CT, Radiography, emergency (pediatric) clinics and outpatient imaging centers.

About Royal Philips Electronics of the Netherlands

Royal Philips Electronics of the Netherlands is a diversified health and well-being company focusing on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of “sense and simplicity". Headquartered in the Netherlands, Philips employs over 122,000 employees with sales and services in more than 100 countries worldwide. With sales of EUR 22.6 billion in 2011, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in male shaving and grooming, portable entertainment and oral healthcare, etc. For more information about Philips, please login: www.philips.com/newscenter

SOURCE　Philips (China) Investment Co., Ltd.

Immune cells "sculpt" circuits in the brain -- by eating away excess connections

Wed, 23 May 2012 16:01:00 +0000

Immune cells "sculpt" circuits in the brain -- by eating away excess connections

PR Newswire

Findings offer a fresh look at developmental and degenerative brain diseases

BOSTON, May 23, 2012 /PRNewswire-USNewswire/ -- We're born with our brains prewired, but as information comes in from our environment, this circuitry is updated. A study from Boston Children's Hospital provides a new glimpse of how this happens: Brain cells known as microglia, tuned into the crosstalk between neurons, literally engulf unnecessary connections, known as synapses, and prune them away.

The study, led by Beth Stevens, PhD, and Dori Schafer, PhD, of the Department of Neurology and the F.M. Kirby Neurobiology Center at Boston Children's Hospital, is the first to capture microglia, previously thought of as immune cells, in the act of eliminating synapses in the healthy, developing brain. The study further shows that microglia take their cues from neurons' activity patterns and from a set of signals called the complement cascade, used by the immune system to rid the body of unwanted pathogens and debris. When complement signaling is disrupted, pruning of synapses is diminished.

The findings, reported online May 23 in the journal Neuron, may have implications for understanding neurodegenerative diseases in which synapses are lost, or developmental disorders such as autism in which synapses are dysfunctional.

Microglia were once thought to play mainly a supportive role in the brain, protecting against disease. Only recently have scientists begun to recognize their involvement in healthy brain development.

"They're gatekeepers that are extremely responsive to changes in the environment," says Stevens, senior investigator on the study. "They're in the brain all the time it's wiring up, and they can move and sense changes in activity."

Stevens first showed in 2007 that defects in the complement system inhibit pruning of synapses, and that neurons are loaded with complement proteins soon after birth -- just when pruning is at its peak. In the new paper, she and Schafer demonstrate that microglia have receptors that recognize the complement protein C3 – the same protein found on synapses that are destined for elimination.

"We think that weaker synapses are being tagged with C3, and that microglia are eliminating them just as macrophages would eliminate bacteria," says Schafer, first author on the paper. "C3 is like an 'eat me' signal."

Mice lacking C3 receptors, or whose microglia had these receptors blocked with a drug, did not eliminate weaker synapses, the researchers showed.

Because microglia are so active, the researchers tracked their activity in mice, using dyes as tracers, and focused on the visual system connecting the eyes and brain, because it is well understood and relatively easy to manipulate.

Stevens thinks that their findings might shed light on diseases that involve synapse loss or dysfunction. In neurodegenerative diseases such as glaucoma, Alzheimer's disease, Lou Gehrig's disease, Huntington's disease and Parkinson's disease, scientists have noted subtle changes in synapses that might cause them to be targeted for elimination. In the healthy adult brain, microglia are in a resting state, but in these diseases, both microglia and the complement system become activated. Stevens and Schafer speculate that targeting microglia, their complement receptors or complement proteins themselves could prevent synapse loss in these diseases.

There are also data suggesting that microglia and/or the complement cascade may be involved in neurodevelopmental disorders such as autism, epilepsy or schizophrenia, perhaps altering the brain's normal balance of synapses.

"All this is still very speculative," Stevens cautions. "We first need to understand normal development."

The study was funded by the Smith Family Foundation, the Dana Foundation, the John Merck Scholars Program, the National Institute of Neurological Disorders and Stroke, an NIH National Research Service Award, the National Institute on Drug Abuse, and the National Institutes of Health.

Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including nine members of the National Academy of Sciences, 11 members of the Institute of Medicine and nine members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 395 bed comprehensive center for pediatric and adolescent health care. Boston Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Boston Children's, visit: http://vectorblog.org.

CONTACT:
Meghan Weber
Boston Children's Hospital
617-919-3110
meghan.weber@childrens.harvard.edu

SOURCE Boston Children's Hospital

Blood Sugar Basics Game Plan Now Available to Help Patients Tackle Type 2 Diabetes

Wed, 23 May 2012 12:00:00 +0000

Blood Sugar Basics Game Plan Now Available to Help Patients Tackle Type 2 Diabetes

Mike Golic, Co-host on ESPN Radio and Former NFL Star Who Has Type 2 Diabetes, Encourages Patients to Start The Blood Sugar Basics Game Plan to Help Manage the Disease

PR Newswire

PHILADELPHIA, May 23, 2012 /PRNewswire/ -- The Blood Sugar Basics Game Plan, developed by the American College of Endocrinology (ACE), with support from Merck (NYSE:MRK) (known as MSD outside the United States and Canada), is kicking off to help the nearly 26 million people in the U.S. who have diabetes find new ways to help manage their disease. The interactive, user-friendly program breaks down diabetes management into four easy-to-understand "goals" to help people with type 2 diabetes take small steps toward better management of their disease.

The program is spearheaded by a trio of Game Plan "coaches:" Mike Golic, co-host of ESPN's Mike & Mike in the Morning and former NFL star who has type 2 diabetes; Farhad Zangeneh, M.D., F.A.C.P., F.A.C.E., a clinical endocrinologist; and Samantha Heller, M.S., R.D., C.D.N., a registered dietitian and exercise physiologist with expertise in diabetes. Each coach contributes unique experience and knowledge to The Game Plan, available on BloodSugarBasics.com.

"When I was first diagnosed with type 2 diabetes, I wasn't sure how I would manage and adjust my lifestyle, but then I thought about it in terms of football and started viewing my doctor as my coach. Together, we worked to develop my personal game plan to help tackle the disease in a way that worked for me," explains Mike Golic. "That's why I am rooting for people with type 2 diabetes to try the Blood Sugar Basics Game Plan – it provides an easy-to-understand approach to help manage the condition through a series of realistic 'goal'-setting steps."

Managing type 2 diabetes can often feel overwhelming, and that's why The Game Plan outlines four personalized goals – Huddle, Enter the Nutrition Zone, Get in the Game, and Check the Scoreboard – that people with type 2 diabetes can put into practice, one at a time, with the help of a healthcare professional.

The first goal of The Game Plan, Huddle, encourages patients to work with a healthcare professional to learn more about type 2 diabetes, including high and low blood sugar and related complications like heart disease, and fill out The Game Plan Playbook to set health goals and develop a personalized game plan to help them get to a diabetes touchdown.

Dr. Zangeneh, the physician advisor to the Blood Sugar Basics program, believes that there is a tremendous need for education about the management of type 2 diabetes. "For example, patients often think about watching for high blood sugar, but do not realize that low blood sugar is also a risk. Low blood sugar is indicated by symptoms such as dizziness and sweating and can be caused by irregular mealtimes, excessive exercise and even certain diabetes medications. Furthermore, low blood sugar can lead to serious consequences including loss of consciousness if it is not treated," he explains.

The second goal of The Game Plan, Enter the Nutrition Zone, helps people take small steps to healthier eating habits. "Changes to your meal plan do not need to be drastic, in fact, they should be made slowly to ensure that they are lasting," advises Samantha Heller. "There are many steps you can take to eat healthier and manage your blood sugar."

After being diagnosed with type 2 diabetes, Golic worked with his doctor to look at his diet and realized that he was still eating like he was an NFL defensive tackle. He explains, "It was easier for me to set small goals to start eating healthier, and I think that's true for most people." In addition to making small changes to his eating habits after retiring from the NFL, Golic worked with his doctor to find ways to incorporate physical activity into his daily routine.

That's where Get in the Game, the third goal, comes into play. "My doctor told me that people with type 2 diabetes are much more likely to develop heart disease than people without diabetes, and that physical activity could help lower my blood pressure and cholesterol levels," says Golic. "Now, I make sure to find some way to be active every day – it could be as simple as taking the stairs instead of the elevator or walking after dinner."

The fourth goal of The Game Plan, Check the Scoreboard, encourages people with type 2 diabetes to celebrate their progress with their biggest fans, like their friends and family, assess what worked for them, and visit with a healthcare professional to continue working toward and maintaining their goals.

To get started on developing your personal Game Plan, visit BloodSugarBasics.com. The website also has other helpful resources including questions to ask your doctor, tips about managing high and low blood sugar, a blood sugar knowledge quiz and checklists on how to help get through episodes of low and high blood sugar.

About Mike Golic

Mike Golic spent nine years as a defensive tackle in the NFL for the Houston Oilers, Philadelphia Eagles and Miami Dolphins. Once he retired, Golic started his broadcast career with a weekly segment on the Randall Cunningham Show and is now one of the namesakes behind the nationally acclaimed radio show Mike & Mike in the Morning on ESPN Radio, which is syndicated through ESPN2 and reaches 98 million Americans every morning. Golic also has type 2 diabetes and encourages other patients to tackle the disease with the Blood Sugar Basics Game Plan.

About Dr. Farhad Zangeneh

Farhad Zangeneh, MD, FACP, FACE is a clinical endocrinologist and medical director of the Endocrine, Diabetes and Osteoporosis Clinic (EDOC) in Sterling, Virginia. He is also an assistant clinical professor of medicine at George Washington University School of Medicine in Washington, D.C. As an expert in the care of people with type 2 diabetes, Dr. Zangeneh is the medical liaison for Blood Sugar Basics, who led the development of The Game Plan.

About Samantha Heller

Samantha Heller, MS, RD, CDN, a registered dietitian and exercise physiologist, is also a Clinical Nutrition Coordinator at the Center for Cancer Care at Griffin Hospital in Derby, Conn. She hosts a live two-hour show, "Samantha Heller's Health and Nutrition Show," on NYU Langone Medical Center's DOCTOR Radio, which airs on SiriusXM, and authored a medically peer-reviewed book titled "Get Smart: Samantha Heller's Nutrition Prescription for Boosting Brain Power and Optimizing Total Body Health." Heller brings years of experience helping type 2 diabetes patients reach their goals for healthy eating and physical activity to The Blood Sugar Basics Game Plan.

About Blood Sugar Basics

Blood Sugar Basics is an educational program aimed to help people living with diabetes, their families and loved ones learn about the importance of controlling blood sugar levels as part of a successful diabetes treatment plan. The program was developed by the American College of Endocrinology (ACE) and supported by Merck. The Game Plan, on BloodSugarBasics.com, is a user-friendly, four-"goal" program to help people with type 2 diabetes in their management of the condition.

About the American College of Endocrinology (ACE)

The American College of Endocrinology (ACE) is the educational and scientific arm of the American Association of Clinical Endocrinologists (AACE). ACE is the leader in advancing the care and prevention of endocrine and metabolic disorders by: Providing professional education and reliable public health information; Recognizing excellence in education, research and service; Promoting clinical research and Defining the future of Clinical Endocrinology.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

SOURCE Merck; American College of Endocrinology

Antibody Drugs: Technologies and Global Markets

Wed, 23 May 2012 11:04:07 +0000

Antibody Drugs: Technologies and Global Markets

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antibody Drugs: Technologies and Global Markets

http://www.reportlinker.com/p0801344/Antibody-Drugs-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide a range of information—from detailed analysis through industry trends—to quantify and qualify the rapidly growing market for therapeutic monoclonal antibody (mAb) drugs. Forecasts and trends are gleaned from industry sources, analyst reports, and company forecasts, as well as from assessment of available and emerging technologies.

The report develops forecasts for sales of the mAb market by individual antibody, by therapeutic antibody target (epidermal growth factor receptor [EGFR], cluster of differentiation [CD] 20, tumor necrosis factor [TNF] alpha, etc.), and by major disease applications from 2011 through 2016. Additionally, we examine strategies employed by biopharmaceutical firms to develop and market products in this explosive market sector.

Our main objective is to present a comprehensive analysis of the current market for therapeutic mAb disease-modifying products and to forecast this market's future direction through 2016.

REASONS FOR DOING THE STUDY

Therapeutic mAbs represent the largest and one of the fastest-growing classes of biopharmaceutical products by sales in the U.S. and throughout the world. Of the top 20 drugs by sales throughout the world today, five are mAbs.

During our forecast period from 2011 through 2016, eight new mAbs are forecast to enter the market, and sales of therapeutic mAbs are estimated to grow from approximately $43 billion in 2010 to nearly $58 billion in 2016. Sales of humanized and fully human antibodies for autoimmune/inflammatory diseases such as rheumatoid arthritis, ulcerative colitis, and multiple sclerosis are forecast to experience the fastest sales growth.

This period of dynamic growth for humanized and fully human antibodies plus the continued rollout of antibody-drug conjugates (ADCs), also called immunoconjugates, is expected to result in stagnating sales of chimeric antibodies from 2011 through 2016.

INTENDED AUDIENCE

This study will be of interest to those working in the biotechnology and pharmaceutical industries and related life science, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug research.

Both individuals looking for a comprehensive listing of mAbs in human clinical-stage development and individuals looking at how the mAb drug marketplace is expected to change (in terms of sales and technology) in the coming years will find this report extremely useful.

SCOPE OF REPORT

This report analyzes and assesses therapeutic applications of mAbs in human medicine. Covered in this report are mAbs exclusively, including the combination of mAbs when they are attached to a cytotoxic agent such as with ADCs.

Excluded from this report are diagnostic uses of mAbs (such as for imaging purposes) and therapeutic antibodies for veterinary use. Also excluded are research applications of mAbs.

The scope of the study is global. The "Overview" section provides a discussion of the importance and advantages of antibody-based products, valuation of antibody product sales, patent issues and differences in applicability of mAbs products versus polyclonal antibodies (pAbs), and other competing agents such as small molecule therapeutics.

The "Technology and Technical Issues" section discusses new directions in antibody research, the types of antibodies used as therapeutics, the challenges in antibody production, and other approaches—in particular transgenic sources—of antibody production.

The "Products" section provides a synopsis of more than 60 mAb drugs, including those currently marketed and those in late-stage development. Comparative product and sales analyses are provided for individual products. Tables include current and forecasted sales by individual product, sales by target and technology (for mAb-based drugs), as well as global market size and growth estimates for therapeutic mAbs.

The "Applications" section provides an overview of the leading indications for available and emerging antibody-based therapeutics. These include selected indications for autoimmune diseases (specifically rheumatoid arthritis, psoriasis, and Crohn's disease), cancer indications (specifically the most common solid tumor types, leukemias, and lymphomas) cardiovascular diseases, infectious diseases, ophthalmic indications, and respiratory diseases.

The "Industry Structure" section provides an overview of the antibody industry as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.

The "Company Profiles" section emphasizes companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

INFORMATION SOURCES

The information in this report was derived from the review of more than 200 biotechnology and pharmaceutical companies developing mAbs and the review of journal articles related to mAb therapeutics. Sources of information include PubMed, ClinicalTrials.gov, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMEA), and company presentations and annual reports.

TABLE OF CONTENTS

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES . 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

INFORMATION SOURCES . 3

ANALYST CREDENTIALS 3

RELATED REPORTS . 3

BCC ON-LINE SERVICES . 4

DISCLAIMER . 4

CHAPTER TWO: SUMMARY 5

SUMMARY TABLE GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2016 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, 2009-2016 ($ MILLIONS) . 6

CHAPTER THREE: OVERVIEW 7

DEFINITIONS 7

DEFINITIONS (CONTINUED) . 8

THE IMPORTANCE OF ANTIBODY DRUGS AND DIAGNOSTICS . 9

THE IMPORTANCE OF ANTIBODY … (CONTINUED) 10

INTELLECTUAL PROPERTY ISSUES AND PATENT LICENSING 11

THE HISTORY OF THE COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS . 11

TABLE 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS . 11

ADVANTAGES OF MONOCLONAL ANTIBODY DRUGS 12

WHY DO MONOCLONAL ANTIBODY PRODUCTS HAVE SO MANY APPLICATIONS COMPARED WITH POLYCLONAL ANTIBODY PRODUCTS? 13

VALUATION OF ANTIBODY PRODUCT SALES . 14

CHAPTER FOUR: TECHNOLOGY AND TECHNICAL ISSUES . 15

OVERVIEW . 15

OVERVIEW (CONTINUED) . 16

TABLE 2 MONOCLONAL ANTIBODIES VERSUS SMALL MOLECULE DRUGS . 17

TABLE 2 (CONTINUED) . 18

TABLE 3 MONOCLONAL ANTIBODIES VERSUS POLYCLONAL ANTIBODIES . 18

THE HAMA PROBLEM AND ITS RESOLUTION . 19

PHAGE DISPLAY AND POLYSOME DISPLAY 20

PHAGE DISPLAY AND POLYSOME … (CONTINUED) 21

DIRECTED EVOLUTION 22

ANTIBODY CLASSES 22

TABLE 4 ANTIBODY TYPES AND DESCRIPTIONS . 23

ANTIBODY FORMS IN PRODUCTS 23

TABLE 5 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES BY ANTIBODY TECHNOLOGY TYPE, THROUGH 2016 ($ MILLIONS) . 24

TABLE 6 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY

ANTIBODY FORM (NUMBER/%) 25

TABLE 7 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TECHNOLOGY FORM AND STAGE OF DEVELOPMENT 25

TABLE 8 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TARGET . 26

ABTIDES 26

ANTIBODY-DRUG CONJUGATES / IMMUNOCONJUGATES 26

ANTISERUMS . 27

BISPECIFIC ANTIBODIES 28

CAMOUFLAGED ANTIBODIES 28

CHIMERIC ANTIBODIES 29

HUMANIZED ANTIBODIES 29

Humanized Antibodies (Continued) . 30

FULLY HUMAN ANTIBODIES 31

PROGENITOR STEM CELLS . 32

SINGLE-CHAIN ANTIBODIES 32

SYNTHETIC ANTIBODIES 33

SOURCES OF MONCLONAL ANTIBODIES ON THE MARKET 34

TABLE 9 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES 34

TABLE 9 (CONTINUED) . 35

TABLE 9 (CONTINUED) . 36

THE SPECIAL CASE OF ENBREL. 36

ANTIBODY TECHNOLOGIES IN DEVELOPMENT 37

AFFIBODIES . 37

DOMAIN ANTIBODIES 37

NANOBODIES . 38

TABLE 10 MONOCLONAL ANTIBODIES IN PHASE 3 DEVELOPMENT 39

TABLE 10 (CONTINUED) . 40

TABLE 11 MONOCLONAL ANTIBODIES IN PHASE 2 DEVELOPMENT 40

TABLE 11 (CONTINUED) . 41

TABLE 11 (CONTINUED) . 42

TABLE 11 (CONTINUED) . 43

TABLE 11 (CONTINUED) . 44

TABLE 11 (CONTINUED) . 45

TABLE 11 (CONTINUED) . 46

TABLE 11 (CONTINUED) 47

TABLE 12 MONOCLONAL ANTIBODIES IN PHASE 1 DEVELOPMENT 47

TABLE 12 (CONTINUED) 48

TABLE 12 (CONTINUED) . 49

TABLE 12 (CONTINUED) . 50

TABLE 12 (CONTINUED) . 51

TABLE 12 (CONTINUED) . 52

NEW DIRECTIONS IN ANTIBODY RESEARCH 53

THE MARKET OPPORTUNITY FOR TRANSGENIC PRODUCTION OF ANTIBODY PRODUCTS 53

THE MARKET OPPORTUNITY FOR …(CONTINUED) 54

THE HIGH COST OF PRODUCING ANTIBODIES AND OTHER PROTEIN DRUGS . 55

THE GROWING CRISIS IN MEETING PRODUCTION DEMANDS FOR PROTEIN DRUGS 56

THE TRANSGENIC ADVANTAGE . 56

TRADITIONAL PRODUCTION METHODS 57

MICROBIAL FERMENTATION . 58

MAMMALIAN CELL CULTURE 58

THE ENBREL SHORTAGE . 59

THE CRUNCH IN CAPACITY. 59

REASONS FOR THE NEED TO INCREASE PROTEIN DRUG PRODUCTION 60

GENOMICS AND GENE DISCOVERY DRIVE THE EXPANDING DEVELOPMENT OF PROTEIN DRUGS 61

PRODUCTION OF ANTIBODIES IN ANIMALS . 62

PRODUCTION OF ANTIBODIES … (CONTINUED) . 63

GOATS AS MONOCLONAL ANTIBODIES FACTORIES 64

PRODUCTION OF ANTIBODIES IN PLANTS 64

PLASTIDS 64

TARGETING AND COMPARTMENTALIZING 65

TRANSGENIC SEEDS FOR ANTIBODY STORAGE 65

CHAPTER FIVE: PRODUCTS 66

OVERVIEW . 66

MARKETED PRODUCTS 66

TABLE 13 GLOBAL SALES OF MONOCLONAL ANTIBODIES, BY

PRODUCT THROUGH 2016 ($ MILLIONS) . 67

TABLE 14 U.S. SALES OF MONOCLONAL ANTIBODIES, BY

PRODUCT THROUGH 2016 ($ MILLIONS) . 68

TABLE 15 REST OF WORLD SALES OF MONOCLONAL ANTIBODIES, BY PRODUCT THROUGH 2016 ($ MILLIONS) . 69

GEMTUZUMAB OZOGAMICIN (MYLOTARG) 70

DACLIZUMAB (ZENAPAX) 71

Daclizumab (Zenapax) (Continued) 72

TABLE 16 DACLIZUMAB CHOICE STUDY RESULTS . 73

CATUMAXOMAB (REMOVAB) 74

TOCILIZUMAB (ACTEMRA, ROACTEMRA, RG1569) . 75

TRASTUZUMAB (HERCEPTIN, RG597) . 76

Trastuzumab (Herceptin, RG597) (Continued) 77

BEVACLIZUMAB (AVASTIN, RG435) . 78

Bevaclizumab (Avastin, RG435) (Continued) 79

Bevaclizumab (Avastin, RG435) (Continued) 80

CETUXIMAB (ERBITUX) . 81

Cetuximab (Erbitux) (Continued) . 82

PANITUMUMAB (VECTIBIX) 83

Panitumumab (Vectibix) (Continued) . 84

IBRITUMOMAB TIUXETAN (ZEVALIN) 85

Results of Trials . 86

Sales of Zevalin 87

ALEMTUZUMAB (LEMTRADA, CAMPATH, MABCAMPATH) 88

Alemtuzumab (… (Continued) 89

Alemtuzumab (… (Continued) 90

NATALIZUMAB (TYSABRI) . 91

TABLE 17 TYSABRI SENTINEL AND AFFIRM STUDY RESULTS 92

Natalizumab (Tysabri) (Continued) 93

TOSITUMOMAB-I (BEXXAR) 94

Tositumomab-I (Bexxar) (Continued) . 95

OFATUMUMAB (ARZERRA) 96

Ofatumumab (Arzerra) (Continued) . 97

RITUXIMAB (RITUXAN, MABTHERA, RG105) . 98

INFLIXIMAB (REMICADE) 99

Infliximab (Remicade) (Continued) . 100

DENOSUMAB (PROLIA, XGEVA) . 101

IPILIMUMAB (YERVOY, MDX-010) 102

ADALIMUMAB (HUMIRA) . 103

GOLIMUMAB (SIMPONI) 104

CANAKINUMAB (ILARIS, ACZ885) 105

ECULIZUMAB (SOLIRIS) . 106

PALIVIZUMAB (SYNAGIS) 107

ABCIXIMAB (REOPRO) 108

Abciximab (ReoPro) (Continued) . 109

Abciximab (ReoPro) (Continued) . 110

RANIBIZUMAB (LUCENTIS) . 111

Ranibizumab (Lucentis) (Continued) 112

MUROMONAB (ORTHOCLONE OKT3) 113

OMALIZUMAB (XOLAIR) . 113

USTEKINUMAB (STELARA, CNTO 1275) 114

Ustekinumab (Stelara, CNTO 1275) (Continued) 115

CERTOLIZUMAB PEGOL (CIMZIA) . 116

BASILIXIMAB (SIMULECT) 116

Basiliximab (Simulect) (Continued) 117

BELIMUMAB (BENLYSTA) . 118

NIMOTUZUMAB . 119

PRODUCTS IN DEVELOPMENT . 119

TANEZUMAB (RN624) 119

VEDOLIZUMAB (MLN0002). 120

LY2127399 121

OTELIXIZUMAB . 121

MEPOLIZUMAB (BOSATRIA) 122

TEPLIZUMAB (MGA031, HOKT3-GAMMA1) . 122

BAPINEUZUMAB (AAB-001) . 123

GANITUMAB (AMG 479) 124

OBINUTUZUMAB (AFUTUZUMAB, GA101, RG7159) 125

ZANOLIMUMAB (FORMERLY HUMAX-CD4) . 126

RESLIZUMAB (CINQUIL) 127

BLINATUMOMAB (MT103) 128

FARLETUZUMAB (MORAB-003) . 128

EPRATUZUMAB 129

GIRENTUXIMAB (RENCAREX) 129

INOTUZUMAB OZOGAMICIN (CMC-544) 130

BRIAKINUMAB (ABT-874) . 131

ELOTUZUMAB 132

SILTUXIMAB (CNTO 328) 133

TRASTUZUMAB EMTANSINE (T-DM1, RG3502) 133

INOLIMOMAB (LEUKOTAC) . 134

ITOLIZUMAB (T1H, ANTI-CD6) 134

NAPTUMOMAB ESTAFENATOX (ANYARA) . 135

NECITUMUMAB (IMC-11F8) . 135

PERTUZUMAB 136

RAMUCIRUMAB (IMC-1121B, LY3009806) 137

RAXIBACUMAB 138

MK-3415, MK-6072, AND MK-3415A . 138

MK-3415, MK-6072, and MK-3415A (Continued) 139

CHAPTER SIX: APPLICATIONS 140

OVERVIEW . 140

TABLE 18 MONOCLONAL ANTIBODIES ON THE MARKET, BY

INDICATION 2011 (NUMBER/%) 140

TABLE 19 GLOBAL SALES OF THERAPEUTIC MONOCLONAL

ANTIBODIES, BY APPLICATION, THROUGH 2016 ($ MILLIONS) . 141

TABLE 20 MONOCLONAL ANTIBODIES IN CLINICAL STAGE DEVELOPMENT, BY INDICATION, 2011 (NUMBER/%) . 141

TABLE 20 (CONTINUED) . 142

AUTOIMMUNE DISEASES 142

CROHN'S DISEASE 143

PSORIASIS . 144

RHEUMATOID ARTHRITIS . 145

TABLE 21 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF INFLAMMATORY DISEASES (NOT INCLUDING MS), THROUGH 2016 ($ MILLIONS) . 145

SOLID TUMORS 146

U.S. CANCER STATISTICS 146

TABLE 22 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2011 . 147

TABLE 23 CANCER PREVALENCE RATES IN THE U.S., 2008 (IN THOUSANDS) . 148

BREAST CANCER . 149

COLORECTAL CANCER 149

HEAD AND NECK CANCER 149

KIDNEY CANCER . 149

LIVER CANCER 149

LUNG CANCER . 150

MALIGNANT MELANOMA 150

OSTEOSARCOMA . 151

OVARIAN CANCER 151

PANCREATIC CANCER . 152

PROSTATE CANCER 152

STOMACH CANCER . 153

ANTIBODY PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER . 153

TABLE 24 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF SOLID TUMORS, BY REGION, THROUGH 2016 ($ MILLIONS) . 153

LYMPHOMAS AND LEUKEMIAS 153

NON-HODGKIN LYMPHOMA . 154

LEUKEMIAS 154

Leukemias (Continued) . 155

CARDIOVASCULAR DISEASES 156

PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY 157

INFECTIOUS DISEASES 158

CYTOMEGALOVIRUS INFECTION 159

HEPATITIS 160

RESPIRATORY SYNCYTIAL VIRUS INFECTION 160

TABLE 25 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF INFECTIOUS DISEASES, BY REGION, THROUGH 2016 ($ MILLIONS) . 161

MULTIPLE SCLEROSIS . 161

TABLE 26 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF MULTIPLE SCLEROSIS, BY REGION, THROUGH 2016 ($ MILLIONS) . 162

OPHTHALMIC DISEASES 162

MACULAR DEGENERATION 162

OTHER THERAPEUTIC APPLICATIONS . 163

TABLE 27 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF OTHER DISEASES, BY REGION, THROUGH 2016 ($ MILLIONS) . 163

CHAPTER SEVEN: INDUSTRY STRUCTURE . 164

OVERVIEW . 164

ORIGINATORS . 164

COMMERCIAL DEVELOPERS . 165

VENDORS . 166

MANUFACTURERS . 166

TECHNOLOGY INNOVATORS. 167

PRICING FORECASTS 168

THE REGULATORY ENVIRONMENT 168

THE REGULATORY ENVIRONMENT (CONTINUED) . 169

GENOMICS AND MONOCLONAL ANTIBODIES: A MATCH FOR SUCCESS . 170

GENOMICS AND MONOCLONAL … (CONTINUED) . 171

GENOMICS AND MONOCLONAL … (CONTINUED) . 172

COMPANY SALES AND MARKET SHARE . 173

TABLE 28 SALES OF MARKETED ANTIBODIES BY

MANUFACTURER, THROUGH 2016 ($ MILLIONS) 174

TABLE 29 MANUFACTURERS OF ANTIBODIES BY MARKET SHARE, 2011 AND 2016 (%) 175

TABLE 30 MONOCLONAL ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY COMPANY . 176

COMPANY PROFILES 176

ABBOTT LABORATORIES . 176

ALEXION PHARMACEUTICALS 177

AMGEN 178

ASTRAZENECA . 179

AstraZeneca – U.S. Headquarters 179

BAYER AG . 180

Bayer (U.S. Location) 180

BIOGEN IDEC . 181

BRISTOL-MYERS SQUIBB 182

BTG . 183

DAIICHI SANKYO . 183

ELAN 184

EMERGENT BIOSOLUTIONS . 185

EISAI 185

ELI LILLY 186

GENMAB 186

Genmab (U.S. Location) 187

GLAXOSMITHKLINE . 187

GlaxoSmithKline (U.S. Location) 187

HUMAN GENOME SCIENCES 188

JOHNSON & JOHNSON . 188

KALOBIOS PHARMACEUTICALS 189

MERCK KGAA (MERCK SERONO) . 190

MORPHOSYS . 191

NOVARTIS . 191

PFIZER . 192

ROCHE . 193

To order this report:Biopharmaceutical Industry: Antibody Drugs: Technologies and Global Markets

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

Wed, 23 May 2012 10:41:31 +0000

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

http://www.reportlinker.com/p0191857/Pharmaceuticals---Global-Group-of-Eight-G8-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu

Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The G8 countries contributed $510,182.1 million in 2010 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.9% between 2006 and 2010.

The G8 countries are expected to reach a value of $629,493.5 million in 2015, with a CAGR of 4.3% over the 2010–15 period.Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 52.1% in 2010.

Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $265,735.9 million in 2010.

The US is expected to lead the Pharmaceuticals industry in the G8 nations with a value of $346,744.2 million in 2015.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs for in-patient and out-patient usage, valued at ex-manufacturer prices.

Any currency conversions used within this report have been calculated using 2010 constant exchange rates.

TABLE OF CONTENTSINTRODUCTION 16What is this report about? 16Who is the target reader? 16Market definition 16GROUP OF EIGHT (G8) PHARMACEUTICALS INDUSTRY OUTLOOK 17PHARMACEUTICALS IN CANADA 24Market overview 24Market value 25Market segmentation 26Market share 27Five forces analysis 28Leading companies 39Market forecasts 50Macroeconomic indicators 51PHARMACEUTICALS IN FRANCE 53Market overview 53Market value 54Market segmentation 55Market share 56Five forces analysis 57Leading companies 68Market forecasts 80Macroeconomic indicators 81PHARMACEUTICALS IN GERMANY 83Market overview 83Market value 84Market segmentation 85Market share 86Five forces analysis 87Leading companies 98Market forecasts 110Macroeconomic indicators 111PHARMACEUTICALS IN ITALY 113Market overview 113Market value 114Market segmentation 115Market share 116Five forces analysis 117Leading companies 128Market forecasts 141Macroeconomic indicators 142PHARMACEUTICALS IN JAPAN 144Market overview 144Market value 145Market segmentation 146Market share 147Five forces analysis 148Leading companies 159Market forecasts 170Macroeconomic indicators 171PHARMACEUTICALS IN RUSSIA 173Market overview 173Market value 174Market segmentation 175Market share 176Five forces analysis 177Leading companies 189Market forecasts 200Macroeconomic indicators 201PHARMACEUTICALS IN THE UNITED KINGDOM 203Market overview 203Market value 204Market segmentation 205Market share 206Five forces analysis 207Leading companies 219Market forecasts 231Macroeconomic indicators 232PHARMACEUTICALS IN THE UNITED STATES 234Market overview 234Market value 235Market segmentation 236Market share 237Five forces analysis 238Leading companies 249Market forecasts 265Macroeconomic indicators 266APPENDIX 268Data Research Methodology 268About Datamonitor 269Disclaimer 269

LIST OF TABLES

Table 1: G8 pharmaceuticals industry, revenue($m), 2006–15 18

Table 2: G8 pharmaceuticals industry, revenue by country ($m), 2006–10 21

Table 3: G8 pharmaceuticals industry forecast, revenue by country ($m), 2010–15 23

Table 4: Canada pharmaceuticals market value: $ million, 2006–10 25

Table 5: Canada pharmaceuticals market segmentation: % share, by value, 2010 26

Table 6: Canada pharmaceuticals market share: % share, by value, 2010 27

Table 7: AstraZeneca PLC: key facts 39

Table 8: AstraZeneca PLC: key financials ($) 41

Table 9: AstraZeneca PLC: key financial ratios 41

Table 10: Johnson & Johnson: key facts 43

Table 11: Johnson & Johnson: key financials ($) 44

Table 12: Johnson & Johnson: key financial ratios 45

Table 13: Pfizer Inc.: key facts 47

Table 14: Pfizer Inc.: key financials ($) 48

Table 15: Pfizer Inc.: key financial ratios 48

Table 16: Canada pharmaceuticals market value forecast: $ million, 2010–15 50

Table 17: Canada size of population (million), 2006–10 51

Table 18: Canada gdp (constant 2000 prices, $ billion), 2006–10 51

Table 19: Canada gdp (current prices, $ billion), 2006–10 51

Table 20: Canada inflation, 2006–10 52

Table 21: Canada consumer price index (absolute), 2006–10 52

Table 22: Canada exchange rate, 2006–10 52

Table 23: France pharmaceuticals market value: $ million, 2006–10 54

Table 24: France pharmaceuticals market segmentation: % share, by value, 2010 55

Table 25: France pharmaceuticals market share: % share, by value, 2010 56

Table 26: AstraZeneca PLC: key facts 68

Table 27: AstraZeneca PLC: key financials ($) 70

Table 28: AstraZeneca PLC: key financial ratios 70

Table 29: GlaxoSmithKline Plc: key facts 72

Table 30: GlaxoSmithKline Plc: key financials ($) 74

Table 31: GlaxoSmithKline Plc: key financials (£) 75

Table 32: GlaxoSmithKline Plc: key financial ratios 75

Table 33: Pfizer Inc.: key facts 77

Table 34: Pfizer Inc.: key financials ($) 78

Table 35: Pfizer Inc.: key financial ratios 78

Table 36: France pharmaceuticals market value forecast: $ million, 2010–15 80

Table 37: France size of population (million), 2006–10 81

Table 38: France gdp (constant 2000 prices, $ billion), 2006–10 81

Table 39: France gdp (current prices, $ billion), 2006–10 81

Table 40: France inflation, 2006–10 82

Table 41: France consumer price index (absolute), 2006–10 82

Table 42: France exchange rate, 2006–10 82

Table 43: Germany pharmaceuticals market value: $ million, 2006–10 84

Table 44: Germany pharmaceuticals market segmentation: % share, by value, 2010 85

Table 45: Germany pharmaceuticals market share: % share, by value, 2010 86

Table 46: GlaxoSmithKline Plc: key facts 98

Table 47: GlaxoSmithKline Plc: key financials ($) 100

Table 48: GlaxoSmithKline Plc: key financials (£) 101

Table 49: GlaxoSmithKline Plc: key financial ratios 101

Table 50: Novartis AG: key facts 103

Table 51: Novartis AG: key financials ($) 104

Table 52: Novartis AG: key financial ratios 105

Table 53: Pfizer Inc.: key facts 107

Table 54: Pfizer Inc.: key financials ($) 108

Table 55: Pfizer Inc.: key financial ratios 108

Table 56: Germany pharmaceuticals market value forecast: $ million, 2010–15 110

Table 57: Germany size of population (million), 2006–10 111

Table 58: Germany gdp (constant 2000 prices, $ billion), 2006–10 111

Table 59: Germany gdp (current prices, $ billion), 2006–10 111

Table 60: Germany inflation, 2006–10 112

Table 61: Germany consumer price index (absolute), 2006–10 112

Table 62: Germany exchange rate, 2006–10 112

Table 63: Italy pharmaceuticals market value: $ million, 2006–10 114

Table 64: Italy pharmaceuticals market segmentation: % share, by value, 2010 115

Table 65: Italy pharmaceuticals market share: % share, by value, 2010 116

Table 66: Chiesi Farmaceutici SpA: key facts 128

Table 67: GlaxoSmithKline Plc: key facts 131

Table 68: GlaxoSmithKline Plc: key financials ($) 133

Table 69: GlaxoSmithKline Plc: key financials (£) 134

Table 70: GlaxoSmithKline Plc: key financial ratios 134

Table 71: Menarini Group, The: key facts 136

Table 72: Pfizer Inc.: key facts 138

Table 73: Pfizer Inc.: key financials ($) 139

Table 74: Pfizer Inc.: key financial ratios 139

Table 75: Italy pharmaceuticals market value forecast: $ million, 2010–15 141

Table 76: Italy size of population (million), 2006–10 142

Table 77: Italy gdp (constant 2000 prices, $ billion), 2006–10 142

Table 78: Italy gdp (current prices, $ billion), 2006–10 142

Table 79: Italy inflation, 2006–10 143

Table 80: Italy consumer price index (absolute), 2006–10 143

Table 81: Italy exchange rate, 2006–10 143

Table 82: Japan pharmaceuticals market value: $ million, 2006–10 145

Table 83: Japan pharmaceuticals market segmentation: % share, by value, 2010 146

Table 84: Japan pharmaceuticals market share: % share, by value, 2010 147

Table 85: Astellas: key facts 159

Table 86: Astellas: key financials ($) 160

Table 87: Astellas: key financials (¥) 161

Table 88: Astellas: key financial ratios 161

Table 89: Daiichi Sankyo Co., Ltd.: key facts 163

Table 90: Daiichi Sankyo Co., Ltd.: key financials ($) 164

Table 91: Daiichi Sankyo Co., Ltd.: key financials (¥) 164

Table 92: Daiichi Sankyo Co., Ltd.: key financial ratios 165

Table 93: Pfizer Inc.: key facts 167

Table 94: Pfizer Inc.: key financials ($) 168

Table 95: Pfizer Inc.: key financial ratios 168

Table 96: Japan pharmaceuticals market value forecast: $ million, 2010–15 170

Table 97: Japan size of population (million), 2006–10 171

Table 98: Japan gdp (constant 2000 prices, $ billion), 2006–10 171

Table 99: Japan gdp (current prices, $ billion), 2006–10 171

Table 100: Japan inflation, 2006–10 172

Table 101: Japan consumer price index (absolute), 2006–10 172

Table 102: Japan exchange rate, 2006–10 172

Table 103: Russia pharmaceuticals market value: $ million, 2006–10 174

Table 104: Russia pharmaceuticals market segmentation: % share, by value, 2010 175

Table 105: Russia pharmaceuticals market share: % share, by value, 2010 176

Table 106: Novartis AG: key facts 189

Table 107: Novartis AG: key financials ($) 190

Table 108: Novartis AG: key financial ratios 191

Table 109: Pharmstandard OJSC: key facts 193

Table 110: Pharmstandard OJSC: key financials ($) 194

Table 111: Pharmstandard OJSC: key financials (RUB) 194

Table 112: Pharmstandard OJSC: key financial ratios 194

Table 113: Sanofi-Aventis SA: key facts 196

Table 114: Sanofi-Aventis SA: key financials ($) 197

Table 115: Sanofi-Aventis SA: key financials (€) 197

Table 116: Sanofi-Aventis SA: key financial ratios 198

Table 117: Russia pharmaceuticals market value forecast: $ million, 2010–15 200

Table 118: Russia size of population (million), 2006–10 201

Table 119: Russia gdp (constant 2000 prices, $ billion), 2006–10 201

Table 120: Russia gdp (current prices, $ billion), 2006–10 201

Table 121: Russia inflation, 2006–10 202

Table 122: Russia consumer price index (absolute), 2006–10 202

Table 123: Russia exchange rate, 2006–10 202

Table 124: United Kingdom pharmaceuticals market value: $ million, 2006–10 204

Table 125: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010 205

Table 126: United Kingdom pharmaceuticals market share: % share, by value, 2010 206

Table 127: AstraZeneca PLC: key facts 219

Table 128: AstraZeneca PLC: key financials ($) 221

Table 129: AstraZeneca PLC: key financial ratios 221

Table 130: GlaxoSmithKline Plc: key facts 223

Table 131: GlaxoSmithKline Plc: key financials ($) 225

Table 132: GlaxoSmithKline Plc: key financials (£) 226

Table 133: GlaxoSmithKline Plc: key financial ratios 226

Table 134: Pfizer Inc.: key facts 228

Table 135: Pfizer Inc.: key financials ($) 229

Table 136: Pfizer Inc.: key financial ratios 229

Table 137: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15 231

Table 138: United Kingdom size of population (million), 2006–10 232

Table 139: United Kingdom gdp (constant 2000 prices, $ billion), 2006–10 232

Table 140: United Kingdom gdp (current prices, $ billion), 2006–10 232

Table 141: United Kingdom inflation, 2006–10 233

Table 142: United Kingdom consumer price index (absolute), 2006–10 233

Table 143: United Kingdom exchange rate, 2006–10 233

Table 144: United States pharmaceuticals market value: $ million, 2006–10 235

Table 145: United States pharmaceuticals market segmentation: % share, by value, 2010 236

Table 146: United States pharmaceuticals market share: % share, by value, 2010 237

Table 147: GlaxoSmithKline Plc: key facts 249

Table 148: GlaxoSmithKline Plc: key financials ($) 251

Table 149: GlaxoSmithKline Plc: key financials (£) 252

Table 150: GlaxoSmithKline Plc: key financial ratios 252

Table 151: Johnson & Johnson: key facts 254

Table 152: Johnson & Johnson: key financials ($) 255

Table 153: Johnson & Johnson: key financial ratios 256

Table 154: Merck & Co., Inc.: key facts 258

Table 155: Merck & Co., Inc.: key financials ($) 259

Table 156: Merck & Co., Inc.: key financial ratios 260

Table 157: Pfizer Inc.: key facts 262

Table 158: Pfizer Inc.: key financials ($) 263

Table 159: Pfizer Inc.: key financial ratios 263

Table 160: United States pharmaceuticals market value forecast: $ million, 2010–15 265

Table 161: United States size of population (million), 2006–10 266

Table 162: United States gdp (constant 2000 prices, $ billion), 2006–10 266

Table 163: United States gdp (current prices, $ billion), 2006–10 266

Table 164: United States inflation, 2006–10 267

Table 165: United States consumer price index (absolute), 2006–10 267

Table 166: United States exchange rate, 2006–10 267

LIST OF FIGURESFigure 1: G8 pharmaceuticals industry, revenue($m), 2006–15 17Figure 2: G8 Pharmaceuticals industry, revenue by country (%), 2010 19Figure 3: G8 pharmaceuticals industry, revenue by country ($m), 2006–10 20Figure 4: G8 pharmaceuticals industry forecast, revenue by country ($m), 2010–15 22Figure 5: Canada pharmaceuticals market value: $ million, 2006–10 25Figure 6: Canada pharmaceuticals market segmentation: % share, by value, 2010 26Figure 7: Canada pharmaceuticals market share: % share, by value, 2010 27Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2010 28Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2010 29Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2010 31Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2010 33Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2010 35Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2010 37Figure 14: AstraZeneca PLC: revenues & profitability 42Figure 15: AstraZeneca PLC: assets & liabilities 42Figure 16: Johnson & Johnson: revenues & profitability 45Figure 17: Johnson & Johnson: assets & liabilities 46Figure 18: Pfizer Inc.: revenues & profitability 49Figure 19: Pfizer Inc.: assets & liabilities 49Figure 20: Canada pharmaceuticals market value forecast: $ million, 2010–15 50Figure 21: France pharmaceuticals market value: $ million, 2006–10 54Figure 22: France pharmaceuticals market segmentation: % share, by value, 2010 55Figure 23: France pharmaceuticals market share: % share, by value, 2010 56Figure 24: Forces driving competition in the pharmaceuticals market in France, 2010 57Figure 25: Drivers of buyer power in the pharmaceuticals market in France, 2010 58Figure 26: Drivers of supplier power in the pharmaceuticals market in France, 2010 60Figure 27: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2010 62Figure 28: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2010 64Figure 29: Drivers of degree of rivalry in the pharmaceuticals market in France, 2010 66Figure 30: AstraZeneca PLC: revenues & profitability 71Figure 31: AstraZeneca PLC: assets & liabilities 71Figure 32: GlaxoSmithKline Plc: revenues & profitability 76Figure 33: GlaxoSmithKline Plc: assets & liabilities 76Figure 34: Pfizer Inc.: revenues & profitability 79Figure 35: Pfizer Inc.: assets & liabilities 79Figure 36: France pharmaceuticals market value forecast: $ million, 2010–15 80Figure 37: Germany pharmaceuticals market value: $ million, 2006–10 84Figure 38: Germany pharmaceuticals market segmentation: % share, by value, 2010 85Figure 39: Germany pharmaceuticals market share: % share, by value, 2010 86Figure 40: Forces driving competition in the pharmaceuticals market in Germany, 2010 87Figure 41: Drivers of buyer power in the pharmaceuticals market in Germany, 2010 88Figure 42: Drivers of supplier power in the pharmaceuticals market in Germany, 2010 90Figure 43: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2010 92Figure 44: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2010 94Figure 45: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2010 96Figure 46: GlaxoSmithKline Plc: revenues & profitability 102Figure 47: GlaxoSmithKline Plc: assets & liabilities 102Figure 48: Novartis AG: revenues & profitability 105Figure 49: Novartis AG: assets & liabilities 106Figure 50: Pfizer Inc.: revenues & profitability 109Figure 51: Pfizer Inc.: assets & liabilities 109Figure 52: Germany pharmaceuticals market value forecast: $ million, 2010–15 110Figure 53: Italy pharmaceuticals market value: $ million, 2006–10 114Figure 54: Italy pharmaceuticals market segmentation: % share, by value, 2010 115Figure 55: Italy pharmaceuticals market share: % share, by value, 2010 116Figure 56: Forces driving competition in the pharmaceuticals market in Italy, 2010 117Figure 57: Drivers of buyer power in the pharmaceuticals market in Italy, 2010 118Figure 58: Drivers of supplier power in the pharmaceuticals market in Italy, 2010 120Figure 59: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2010 122Figure 60: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2010 124Figure 61: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2010 126Figure 62: GlaxoSmithKline Plc: revenues & profitability 135Figure 63: GlaxoSmithKline Plc: assets & liabilities 135Figure 64: Pfizer Inc.: revenues & profitability 140Figure 65: Pfizer Inc.: assets & liabilities 140Figure 66: Italy pharmaceuticals market value forecast: $ million, 2010–15 141Figure 67: Japan pharmaceuticals market value: $ million, 2006–10 145Figure 68: Japan pharmaceuticals market segmentation: % share, by value, 2010 146Figure 69: Japan pharmaceuticals market share: % share, by value, 2010 147Figure 70: Forces driving competition in the pharmaceuticals market in Japan, 2010 148Figure 71: Drivers of buyer power in the pharmaceuticals market in Japan, 2010 149Figure 72: Drivers of supplier power in the pharmaceuticals market in Japan, 2010 151Figure 73: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2010 153Figure 74: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2010 155Figure 75: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2010 157Figure 76: Astellas: revenues & profitability 162Figure 77: Astellas: assets & liabilities 162Figure 78: Daiichi Sankyo Co., Ltd.: revenues & profitability 165Figure 79: Daiichi Sankyo Co., Ltd.: assets & liabilities 166Figure 80: Pfizer Inc.: revenues & profitability 169Figure 81: Pfizer Inc.: assets & liabilities 169Figure 82: Japan pharmaceuticals market value forecast: $ million, 2010–15 170Figure 83: Russia pharmaceuticals market value: $ million, 2006–10 174Figure 84: Russia pharmaceuticals market segmentation: % share, by value, 2010 175Figure 85: Russia pharmaceuticals market share: % share, by value, 2010 176Figure 86: Forces driving competition in the pharmaceuticals market in Russia, 2010 177Figure 87: Drivers of buyer power in the pharmaceuticals market in Russia, 2010 179Figure 88: Drivers of supplier power in the pharmaceuticals market in Russia, 2010 181Figure 89: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2010 183Figure 90: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2010 185Figure 91: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2010 187Figure 92: Novartis AG: revenues & profitability 191Figure 93: Novartis AG: assets & liabilities 192Figure 94: Pharmstandard OJSC: revenues & profitability 195Figure 95: Sanofi-Aventis SA: revenues & profitability 198Figure 96: Sanofi-Aventis SA: assets & liabilities 199Figure 97: Russia pharmaceuticals market value forecast: $ million, 2010–15 200Figure 98: United Kingdom pharmaceuticals market value: $ million, 2006–10 204Figure 99: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010 205Figure 100: United Kingdom pharmaceuticals market share: % share, by value, 2010 206Figure 101: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2010 207Figure 102: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2010 209Figure 103: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2010 211Figure 104: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2010 213Figure 105: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2010 215Figure 106: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2010 217Figure 107: AstraZeneca PLC: revenues & profitability 222Figure 108: AstraZeneca PLC: assets & liabilities 222Figure 109: GlaxoSmithKline Plc: revenues & profitability 227Figure 110: GlaxoSmithKline Plc: assets & liabilities 227Figure 111: Pfizer Inc.: revenues & profitability 230Figure 112: Pfizer Inc.: assets & liabilities 230Figure 113: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15 231Figure 114: United States pharmaceuticals market value: $ million, 2006–10 235Figure 115: United States pharmaceuticals market segmentation: % share, by value, 2010 236Figure 116: United States pharmaceuticals market share: % share, by value, 2010 237Figure 117: Forces driving competition in the pharmaceuticals market in the United States, 2010 238Figure 118: Drivers of buyer power in the pharmaceuticals market in the United States, 2010 239Figure 119: Drivers of supplier power in the pharmaceuticals market in the United States, 2010 241Figure 120: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2010 243Figure 121: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2010 245Figure 122: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2010 247Figure 123: GlaxoSmithKline Plc: revenues & profitability 253Figure 124: GlaxoSmithKline Plc: assets & liabilities 253Figure 125: Johnson & Johnson: revenues & profitability 256Figure 126: Johnson & Johnson: assets & liabilities 257Figure 127: Merck & Co., Inc.: revenues & profitability 260Figure 128: Merck & Co., Inc.: assets & liabilities 261Figure 129: Pfizer Inc.: revenues & profitability 264Figure 130: Pfizer Inc.: assets & liabilities 264Figure 131: United States pharmaceuticals market value forecast: $ million, 2010–15 265

To order this report:Pharmaceutical Industry: Pharmaceuticals - Global Group of Eight (G8) Industry Guide

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Wed, 23 May 2012 10:07:26 +0000

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

http://www.reportlinker.com/p0866960/Arthritis-Therapeutics-Market-to-2018---Novel-Oral-JAK-Inhibitors-and-Biologic-Disease-Modifying-Anti-Rheumatic-Drugs-DMARD-Will-Drive-Continued-Growth-Across-Key-Indications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Summary

GBI Research's new report, "Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications", provides an expert insight into the global arthritis market and market forecast until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the top four arthritis therapeutic indications which are osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape of the top companies in the market and an analysis of the key trends in mergers and acquisitions, and licensing agreements involving arthritis therapies.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the global arthritis therapeutics market was estimated at $20.6 billion in 2010, during the forecast period the market grow at a Compound Annual Growth Rate (CAGR) of 7.2% between 2010 and 2018 to a $38 billion. The market share of rheumatoid arthritis, osteoarthritis, psoriatic arthritis and ankylosing spondylitis in the overall arthritis market was 68%, 22%, 7.4% and 2.6%, respectively, in 2010. The rheumatoid arthritis market was $14 billion in 2010. The market revenue is expected to increase to $26.9 billion by 2018 at a CAGR of 8.5%. The osteoarthritis market is expected to show slower growth among the top four indications. Top six companies in the arthritis therapeutics market accounted for a share of close to 62% in 2010, leaving 38% of the market dominated by generic therapies and smaller players. Despite a significant number of products available on the market, the high value of biologics keeps the market value high.

GBI Research analysis shows that the Research and Development (R&D) pipeline for the arthritis therapeutics market is strong. The rich arthritis pipeline is likely to support the growth of this market thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are already active in R&D for arthritis therapies.

Scope

- Data and analysis of the arthritis market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan. - Annualized market data for the osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis markets from 2004 to 2010, with forecasts to 2018.- Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.- Key drivers and restraints that have had a significant impact on the market - The competitive landscape of the arthritis market which includes companies such as Johnson & Johnson, Abbott, Amgen, Pfizer, Roche and Bristol-Myers Squibb.- Key M&A activities and licensing agreements that took place from 2005 to 2011 in the arthritis market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.- Device a more tailored country strategy by understanding the key drivers and barriers of the arthritis market.- Develop key strategic initiatives by understanding the key focus areas of the leading companies.- Accelerate and strengthen your market position by identifying the key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 112 Arthritis Therapeutics Market to 2018 - Introduction 123 Arthritis Therapeutics Market to 2018 - Market Overview 143.1 Introduction 143.2 Revenue Forecasts for the Global Arthritis Therapeutics Market 153.2.1 Revenue 153.2.2 Annual Cost of Treatment 163.3 Treatment Usage Patterns 173.3.1 Diseased Population 183.3.2 Treatment Seeking Population 183.3.3 Diagnosis Population 183.3.4 Prescription Population 194 Arthritis Therapeutics Market to 2018 - Therapeutic Landscape 204.1 Osteoarthritis Therapeutics Market 204.1.1 Introduction 204.1.2 Epidemiology 214.1.3 Symptoms 214.1.4 Diagnosis 214.1.5 Diagnostic Imaging Techniques 224.1.6 Treatment 224.1.7 Revenue 254.1.8 Annual Cost of Treatment 264.1.9 Treatment Usage Patterns 274.1.10 Marketed Products 294.2 Drivers and Barriers for the Osteoarthritis Therapeutics Market 304.2.1 Drivers for the Osteoarthritis Therapeutics Market 304.2.2 Barriers for the Osteoarthritis Therapeutics Market 304.3 Opportunity and Unmet Need 314.4 Arthritis Therapeutics Market 324.4.1 Introduction 324.4.2 Epidemiology 334.4.3 Symptoms 334.4.4 Diagnosis 344.4.5 Diagnostic Techniques 344.4.6 Treatment 354.4.7 Non-Pharmacological Therapy 364.4.8 Surgical Treatment 364.4.9 Pharmacological Therapy 364.4.10 Revenue 374.4.11 Annual Cost of Treatment 384.4.12 Treatment Usage Patterns 394.4.13 Marketed products 414.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 424.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market 424.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market 424.6 Opportunity and Unmet Needs 434.7 Psoriatic Arthritis Therapeutics Market 434.7.1 Introduction 434.7.2 Epidemiology 444.7.3 Symptoms 444.7.4 Diagnosis 444.7.5 Diagnostic Techniques 444.7.6 Treatment 454.7.7 Non-Pharmacological Therapy 454.7.8 Pharmacological Therapy 454.7.9 Surgery 464.7.10 Revenue 464.7.11 Annual Cost of Treatment 474.7.12 Treatment Usage Patterns 484.7.13 Marketed Products 504.8 Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market 514.8.1 Drivers for the Psoriatic Arthritis Therapeutics Market 514.8.2 Barriers for the Psoriatic Arthritis Therapeutics Market 514.9 Opportunity and Unmet Needs 514.10 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market 524.10.1 Introduction 524.10.2 Epidemiology 524.10.3 Symptoms 534.10.4 Diagnosis 534.10.5 Treatment 544.10.6 Non-Pharmacological Therapy 544.10.7 Pharmacological Therapy 554.10.8 Surgery 564.10.9 Revenue 564.10.10 Annual Cost of Treatment 574.10.11 Treatment Usage Patterns 584.10.12 Marketed products 604.11 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market 604.11.1 Drivers for the Ankylosing Spondylitis Therapeutics Market 604.11.2 Barriers for the Ankylosing Spondylitis Therapeutics Market 604.12 Opportunity and Unmet Need 615 Arthritis Therapeutics Market to 2018 - Geographical Landscape 625.1 Revenue Analysis by Geography 625.2 The US 635.2.1 Revenue 635.2.2 Annual Cost of Treatment 655.2.3 Treatment Usage Patterns 665.3 Top Five European countries (UK, Germany, France, Italy and Spain) 685.3.1 Revenue 685.3.2 Annual Cost of Treatment 695.3.3 Treatment Usage Patterns 705.4 Japan 725.4.1 Revenue 725.4.2 Annual Cost of Treatment 735.4.3 Treatment Usage Patterns 746 Arthritis Therapeutics Market to 2018 - Product Pipeline Analysis 766.1 Introduction 786.1.1 Research and Development Pipeline – Osteoarthritis 786.2 Introduction 836.2.1 Research and Development Pipeline – Rheumatoid Arthritis 836.3 Introduction 956.3.1 Research and Development Pipeline – Psoriasis Arthritis 956.4 Introduction 966.4.1 Research and Development Pipeline – Ankylosing Spondylitis 966.5 Profiles of Promising Drugs in the Pipeline 986.5.1 Tofacitinib (CP-690550) 986.5.2 Ofatumumab 996.5.3 Secukinumab (AIN457) 996.5.4 Fostamatinib (R788) 1006.5.5 LY2127399 (Tabalumab) 1016.5.6 REGN88 (SAR153191) 1026.5.7 LT-NS001 1037 Arthritis Therapeutics Market to 2018 - Competitive Landscape 1047.1 Market Share Analysis 1047.1.1 Major Players 1047.2 Competitive Profile 1057.2.1 Roche 1057.2.2 Johnson & Johnson 1077.2.3 Pfizer 1087.2.4 Abbott Laboratories 1107.2.5 Bristol-Myers Squibb 1117.2.6 Amgen 1128 Arthritis Therapeutics Market to 2018 - Strategic Consolidations 1138.1 Mergers and Acquisitions 1138.1.1 Overview 1138.1.2 Major Merger and Acquisition Deals 1138.1.3 Possible Future Merger and Acquisition Deals 1198.2 Licensing Agreements 1208.2.1 Overview 1208.2.2 Major Licensing Deal 1208.3 Co-Development Agreements 1268.4 Deals by Geography 1328.5 Deals by Value 1339 Arthritis Therapeutics Market to 2018 - Appendix 1349.1 Market Definitions 1349.2 Abbreviations 1349.3 Sources 1359.4 Research Methodology 1369.4.1 Coverage 1369.4.2 Secondary Research 1369.4.3 Primary Research 1379.4.4 Forecasts 1379.4.5 Expert Panel Validation 1409.5 Contact Us 1409.6 Disclaimer 140

List of Tables

1.1 List of TablesTable 1: Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 15Table 2: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 16Table 3: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 16Table 4: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 17Table 5: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 17Table 6: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 18Table 7 : Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 25Table 8: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 26Table 9: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 26Table 10: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 26Table 11: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 27Table 12: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 28Table 13: Osteoarthritis Therapeutics Market, Marketed Products, 2010 29Table 14: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 37Table 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 37Table 16: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 38Table 17: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 38Table 18: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 39Table 19: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 40Table 20: Rheumatoid Arthritis Therapeutics-Marketed Products, 2010 41Table 21: Psoriatic Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 47Table 22: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 47Table 23: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 47Table 24: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 48Table 25: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 49Table 26: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 49Table 27: Psoriatic Arthritis Therapeutics-Marketed Products, 2010 50Table 28: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2004-2010 56Table 29: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 56Table 30: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 57Table 31: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 57Table 32: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 58Table 33: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 59Table 34: Ankylosing Spondylitis Therapeutics-Marketed Products, 2010 60Table 35: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2010 63Table 36: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018 63Table 37: Arthritis Therapeutics Market, The US, Revenue ($bn), 2004-2010 64Table 38: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018 64Table 39: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2004-2010 65Table 40: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2010-2018 65Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010 66Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 66Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010 68Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018 68Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010 69Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018 69Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010 70Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018 71Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010 72Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018 72Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010 73Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 73Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010 74Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 74Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 79Table 56: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 80Table 57: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Develoment Stage Molecules, 2011 80Table 58: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 81Table 59: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82Table 60: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82Table 61: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 84Table 62: Arthritis Therapeutics Market, Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 85Table 63: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 86Table 64: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 87Table 65: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 88Table 66: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 89Table 67: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 90Table 68: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 92Table 69: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 93Table 70: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 94Table 71: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 95Table 72: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 96Table 73: Arthritis Therapeutics Market- Ankylosing Spondylitis Pipeline, Development Stage Molecules, 2011 97

List of Figures

1.2 List of FiguresFigure 1: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 15Figure 2: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 16Figure 3: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 17Figure 4: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 25Figure 5: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 26Figure 6: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 27Figure 7: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 37Figure 8: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 38Figure 9: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 39Figure 10: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 46Figure 11: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 47Figure 12: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 48Figure 13: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018 56Figure 14: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 57Figure 15: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 58Figure 16: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2018 62Figure 17: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018 64Figure 18: Arthritis Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2018 65Figure 19: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2018 66Figure 20: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2004-2018 68Figure 21: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2018 69Figure 22: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2018 70Figure 23: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2004-2018 72Figure 24: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2018 73Figure 25:Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2018 74Figure 26:Arthritis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 76Figure 27: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 77Figure 28: Arthritis Therapeutics Market, Osteoarthritis Therapeutics, Global R&D Pipeline by Phase (%), 2011 78Figure 29: Arthritis Therapeutics Market-Rheumatoid Arthritis, Global R&D Pipeline by Phase (%), 2011 83Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 95Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 96Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010 104Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011 106Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011 107Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011 109Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011 110Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 111Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011 112Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011 132Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011 133Figure 41: GBI Research Market Forecasting Model 139

Companies Mentioned

RocheJohnson & JohnsonPfizerAbbott LaboratoriesBristol-Myers SquibbAmgen

To order this report:Therapy Industry: Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts

Wed, 23 May 2012 09:25:38 +0000

Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts

http://www.reportlinker.com/p0865302/Non-Insulin-Diabetes-Management-Products-Players-Markets-and-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

The diabetes market is changing. The convergence of environmental factors, lifestyle factors and increased patient longevity are driving double-digit growth projections for the incidence of non-insulin dependent (Type 2) diabetes globally. Type 2 diabetes accounts for about 90% of all diagnosed cases of diabetes and is increasingly being diagnosed in children and adolescents. There are eight drug classes, analyzed in this report, with proven efficacy for aiding in glycemic control in this patient population. Because of the size and business potential of this market, pipeline activity is high. In addition to derivative products and products that combine approved APIs in a single dosage form, drugs based on newer chemistries and mechanisms that include amylin analogs and GLP-1 drugs have been introduced. Globally, revenues of drugs for managing Type 2 diabetes will grow by 14% between 2011 and 2016. Safety issues associated with post-launch-reported events will continue to be a major concern for market participants.

Highlights

· Analyzes and evaluates non-insulin or insulin analog drug products and development-stage candidates for glycemic control

· Provides assessments of diabetes managemnet markets for non-insulin drugsl and examines key market and commercialization factors

· Evaluates the impact of economic, technology, and regulatory factors on diabetes management markets

· Provides market data and forecasts to 2016

· Profiles market sector participants, their product development activities and business strategies

Summary of Contents

Executive Summary

Diabetes Management Market Dynamics

The Economics of Diabetes

Therapeutic Options and Patient Outcomes

Evolving Healthcare Initiatives

Demand Drivers

Competitive Landscape

Risk Factors

Non-Insulin Diabetes Management – Product Development Factors

Formulation and Administration

Oral Form Factors

Injectable Formulations

Dosing Frequency

Injectable Device Strategies

Clinical Trial Factors

Combination Therapeutics

Non-Insulin Drug Therapeutics – Classes, Mechanisms and Prescribing Factors

Alpha-glucosidase Inhibitors

Amylin Analogs

Di-peptidyl peptidase IV

Glitazones (Thiazolidinediones)

Glucagon-Like Peptide-1 (GLP-1)

Metformin

Meglitinides

Sulfonylureas

Non-Insulin Drug Therapeutics – Commercial Product Assessments

Branded Drugs

Alpha-glucosidase Inhibitors

Glyset (Miglitol)

Precose (Acarbose)

Amylin Analogs

Symlin (pramlintide acetate)

Dipeptidyl peptidase IV

Januvia (Sitagliptin)

Onglyza (BMS)

Tradjenta (Linagliptin)

Glitazones (Thiazolidinediones)

Pioglitazones

Rosiglitazones

Glucagon-Like Peptide-1 (GLP-1)

Byetta (Amylin)

Bydureon (Amylin)

Victoza (NovoNordisk)

Meglitinides

Starlix (Nateglinide)

Prandin (Repaglinide)

Sulfonylureas

Glipizide

Glimepirides

Other Therapeutic Classes

Dopamine Receptor Agonists

Combination Drug Products

Actoplus Met (Takeda)

Avandamet (GloxoSmithKline)

Avandaryl (GlaxoSmithKline)

Duetact (Takeda)

Glucovance (BMS)

Janumet (Merck)

Jentadueto (Boehringer Ingelheim)

Kombiglyze XR (BMS)

Metaglip (BMS)

Prandimet (NovoNordisk)

Commercialized Drugs Not Approved by the FDA

Alpha-glucosidase Inhibitors

Basen (Voglibose)

Alogliptin

Galvus (Vildagliptin)

Nesina

Generic Non-Insulin Diabetes Management Drugs

Pipeline Candidates - Analysis and Prospects

Dipeptidyl peptidase IV

Dutogliptin (Phenomix)

Gemigliptin (LG Life Sciences)

Glucagon-Like Peptide-1 (GLP-1)

Lyxumia (Lixisenatide)

Syncria (GlaxoSmithKline)

Peroxisome Proliferator-activated Receptor agonist (PPAR)

Aleglitazar

SGLT2 Inhibitors

Dapagliflozin

Canagliflozin

Non-Insulin Diabetes Management - Market Segment Analysis & Forecasts

Analysis and Forecasts by Drug Class

Analysis and Forecasts by Region

Market Factors

Regulatory Factors

North America

European Union

Japan

Demographic Factors

Safety and Reporting

Patient Compliance Factors

Sector Participant Company Profiles

To order this report:Drug and Medication Industry: Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments

Wed, 23 May 2012 07:00:00 +0000

New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments

PR Newswire

LONDON, May 23, 2012 /PRNewswire/ --

According to Cold Chain IQ findings, nearly 30% of individuals surveyed reported temperature excursions in 6% or more of their temperature sensitive pharmaceutical product. Temperature excursions of pharmaceutical products can not only result in product losses, but also endanger patient lives.

Cold Chain IQ presents a new report examining temperature excursions in the distribution chain for clinical and commercial products and leading strategies that the pharmaceutical industry is employing to improve the storage and handling of temperature sensitive products.

Cold Chain IQ, the online resource for the temperature controlled supply industry has published the state of the industry report "Operating a Global Temperature Controlled Supply Chain."

This definitive research report looks at technologies and strategies the industry is employing to leverage partnerships and streamline processes in supply chains of temperature sensitive products.

Over the past year Cold Chain IQ conducted interviews with over 100 experts from all stages of the pharmaceutical and medical distribution chain from logistics to quality assurance, regulators to manufacturers. In this report we share their key challenges and strategies to overcome these.

Contributors include global heads of cold chain and experts from Latin America IMF, Pfizer, Word Courier Group, Roche, Eli Lilly, Modality Solutions, AMAG, Merck, Exelsius Cold Chain, Novo Nordisk, DHL, MacroGenics, Laminar Medica, Logistics Institute of Asia Pacific and South African Refrigerated Distribution Association as well as unique perspective from 300+ global attendees from the 11th Annual Cool Chain Logistics Europe industry forum.

The 28 page report features in-depth insight on the rise of emerging markets, reverse logistics, the increased push towards eco initiatives, CRT and quality management systems as well as a detailed overview of the industry.

"We predict 8 of the top 10 best-selling global drug products will require cold chain storage and handling by 2016 - this report is essential for anyone competing in the BioPharma industry," said Courtney Becker-James, Director, Cold Chain IQ.

Key Findings:

96% consider cold chain or temp control a core competency of their logistics provider
BRIC in 5 years: China will present the greatest opportunity
63% said finding cost-effective solutions / products is their key challenge in the storage and distribution of CRT and ambient products
71% of pharmaceutical distribution professionals plan to increase investment over the next 10 years

To learn the rest of the results and conclusions, read the full report here:

http://www.coldchainiq.com/supply-chain-security/white-papers/research-report-operating-a-global-temperature-con/

ColdChainIQ.com is designed for the life science logistics and quality community to share ideas, expertise and solutions, and provides members with cutting edge information and expertise as well as the opportunity to network with both their peers and key industry authorities.

For more information contact Cold Chain IQ on info@coldchainiq.com

Andrea Charles
Editor
Andrea.charles@iqpc.co.uk

Sumit Dutta
Marketing Manager
Sumit.dutta@iqpc.co.uk

IQPC
129 Wilton Road, Victoria, London SW1V 1JZ
+44(0)207-368-9300

New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments

Wed, 23 May 2012 07:00:00 +0000

New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments

PR Newswire

LONDON, May 23, 2012 /PRNewswire/ --

Cold Chain IQ, the online resource for the temperature controlled supply industry has published the state of the industry report "Operating a Global Temperature Controlled Supply Chain."

This definitive research report looks at technologies and strategies the industry is employing to leverage partnerships and streamline processes in supply chains of temperature sensitive products.

Key Findings:

96% consider cold chain or temp control a core competency of their logistics provider
BRIC in 5 years: China will present the greatest opportunity
63% said finding cost-effective solutions / products is their key challenge in the storage and distribution of CRT and ambient products
71% of pharmaceutical distribution professionals plan to increase investment over the next 10 years

To learn the rest of the results and conclusions, read the full report here:

http://www.coldchainiq.com/supply-chain-security/white-papers/research-report-operating-a-global-temperature-con/

SOURCE ColdChainIQ.com

P-MEC China and Co-Located Shows Provide Access to Growing Markets and Debut Zoning

Wed, 23 May 2012 02:00:00 +0000

P-MEC China and Co-Located Shows Provide Access to Growing Markets and Debut Zoning

PR Newswire

AMSTERDAM, May 23, 2012 /PRNewswire-Asia/ -- Leading events organiser UBM Live( http://www.ubmlive.com ) today announced details of the forthcoming P-MEC China, to be hosted 26th to 28th June, 2012 at the SNIEC in Shanghai, China. P-MEC China, for pharmaceutical machinery and equipment resources, will be co-located with a Pharma portfolio of events including CPhI China for pharmaceutical ingredients, ICSE China for contract and outsourced services, BioPh China for the biopharmaceutical sector, InnoPack China for innovative packaging services and solutions and LABWorld China for laboratory and analytical equipment needs. Over three days, the portfolio will provide a single location for visitors to access products, services and solutions across the diverse sectors of the pharmaceutical industry. Combined, the annual events are once again expected to host more than 27,000 attendees and 1,700 exhibitors. P-MEC China alone will feature over 100 conferences, seminars and technical workshops focused on the growing pharmaceutical manufacturing sector in China, and will host more than 450 exhibitors showcasing products and services tailored to the pharmaceutical manufacturing sector.

(Logo: http://www.prnasia.com/sa/2010/04/19/20100419602891.jpg )

(Logo: http://www.prnasia.com/sa/2012/02/22/20120222113811549389-l.jpg )

"China's growing technology and engineering skills have made it an increasingly attractive destination for pharma companies to partner with. Growth has proved consistent across the various sectors of this emerging pharmaceutical market, with particular strength shown in the pharmaceutical manufacturing sector. An aging global population, improved global healthcare system regulations and the rise of generics are all factors that continue to play into this growth. In fact, the strong outlook for pharmaceutical manufacturing in China includes an 8.7 percent predicted annual increase in the demand for packaging machinery in China through 2014(Source 1)," UBM Brand Director, Haf Cennydd commented. She further stated that, "Price, quality and customer service have come to the forefront as Asian companies realise that they cannot afford the long periods of downtime caused by old or ineffective machinery. As Asia improves machinery in order to meet GMP standards, western countries will now have access to upmarket machinery at downmarket prices."

A new zone-based layout is being introduced at P-MEC China and co-located events in 2012. The zoning layout promises to ease navigation throughout the events in order to minimise walking and maximise meeting time for visitors. Specifically, P-MEC China will feature a general zone, a machinery and equipment zone and an environmental protection and clean technology zone. The new InnoPack China event will provide a dedicated pharmaceutical packaging zone and co-located event, CPhI China will feature zones for general ingredients, APIs, intermediates, fine chemicals and natural extracts, while ICSE China will be split between contract services and outsourcing.

"Zoning will enable easier navigation of the events and give attendees and exhibitors more face time to do business," continued Cennydd. "In P-MEC China, the new zone offerings have been introduced in response to current market demands and upcoming projected changes. For instance, the new Environmental Protection and Clean Technology zone in P-MEC was added in response to industry expectations that the Chinese government will announce new GMP manufacturer regulations for environmental protection in 2013 and beyond. Industry experts believe that changes like this will create great demand, including an estimated US$47.5M for air cleaning systems alone(Source 2). The new zones help to highlight various solutions for these changing industry needs and reflect the UBM commitment to ensuring that our events stay in tune with the market and add value year over year as the Chinese pharma market continues to grow and the regulatory environment evolves."

To learn more about P-MEC China and co-located events InnoPack China, LABWorld China, BioPh China, CPhI China and ICSE China, or to register to attend, please visit www.pmec-china.com.

The UBM Live annual schedule of Pharmaceutical events also includes CPhI South East Asia (10-12 May, 2012 at the Jakarta International Expo in Indonesia), ICSE USA (22-23 May, 2012 at the Pennsylvania Convention Centre in Philadelphia, PA), CPhI, ICSE and BioPh South America (21-23 August, 2012 at the Transamerica Expo Center in Sao Paulo, Brazil), CPhI Worldwide, ICSE, P-MEC and InnoPack (9-11 October, 2012 at the Feria de Madrid, Spain), CPhI and P-MEC India (21-23 November, 2012 at the Bombay Exhibition Centre in Mumbai) and CPhI, ICSE, P-MEC and Pharmatec Japan (24-26 April, 2013 at the Tokyo Big Sight Exhibition Centre in Japan).

Sources:

-- Freedonia Group, 'Packaging Machinery in China'

-- CHEManager Online, 'APIs in China: Pharma Industry Booming in Asia'

Notes for Editors:

UBM Live is a division of UBM Plc (LSE: UBM) a leading provider of business information services to the maritime, travel, fashion, technology, healthcare, media, and property industries. UBM offers services in trade shows, online, news distribution, and publishing to customers across the globe. Its brands are represented in more than 30 countries and are organized into specialist teams that serve their business communities helping them excel in their market by working effectively and efficiently. For more information, go to www.ubmlive.com.

Media Enquiries: Company Enquiries:

Impress Labs UBM Live

Global (excl. North America): Richard Kerns Haohao Chen

richard@impresslabs.com Tel: +31-20-40-99-593

Tel: +44-161-728-5880

North America: Beth Willers

beth@impresslabs.com

Tel: +1-503-928-7828

SOURCE　UBM Live

New Zoning to Highlight High-Growth Sectors at China Pharma Events

Wed, 23 May 2012 02:00:00 +0000

New Zoning to Highlight High-Growth Sectors at China Pharma Events

PR Newswire

AMSTERDAM, May 23, 2012 /PRNewswire-Asia/ -- Leading events organiser UBM Live( http://www.ubmlive.com ) today announced details of its annual schedule of China events for the global pharmaceutical market. Set to be hosted from 26th to 28th June at the SNIEC in Shanghai, CPhI China for pharmaceutical ingredients, and ICSE China for contract and outsourced services, will be co-located with BioPh China for the biopharmaceutical sector, InnoPack China for innovative packaging services and solutions, and LABWorld China for laboratory and analytical equipment needs. The combined events are expected to host more than 27,000 attendees and 1,700 diverse exhibitors. Attendees of the 2012 China Pharma Portfolio of events will also be able to take advantage of the introduction of zoning, designed to highlight high-growth sectors within the Chinese market and facilitate easier navigation of the events for maximised visitor ROI.

(Logo: http://www.prnasia.com/sa/2010/04/19/20100419602891.jpg )

(Logo: http://www.prnasia.com/sa/2012/02/22/20120222113118191988-l.jpg )

"The size and synergies of CPhI China, ICSE China and the co-located events create a dedicated marketplace for companies to find products and services, including standard and custom APIs. In the Asian pharma market, an increased emphasis has been placed on producing high quality drugs faster as many blockbuster drug patents expire. There is a large interest in generics and biosimilars, as the market demands better versions of drugs at a cheaper price. Statistics have shown that the Chinese market could double as the country improves its health care systems and regulations and IMS Health projected that drug revenue in China would grow by $40 billion through 2013(Source 1)," UBM Brand Director, Haf Cennydd noted. "Active Pharmaceutical Ingredients (APIs) make up more than 50% of the export value of China's pharmaceutical trade and is it estimated that the Chinese market for APIs will witness a compound growth rate of 18% from 2010 to 2017(Source 2). In this flourishing environment CPhI China, ICSE China and co-located events are the only events of their kind that can offer direct access to so many sectors of the Chinese pharmaceutical industry."

Successfully introduced at the CPhI Worldwide events, the new zoning format aims to increase visitor ROI while onsite and supports the goal of more time spent meeting with colleagues and less time spent navigating the exhibition halls. Within the events, there are zones targeted towards specific products and services which will make contacts easier to find the first time. CPhI China will feature new zones for general ingredients, APIs, intermediates, fine chemicals, and natural extracts. ICSE China will be split between contract services and outsourcing, while BioPh China will remain dedicated to biopharmaceuticals only. Co-located event, P-MEC China, will feature a general zone, as well as one for machinery and equipment and one for environment protection and clean technology.

A modular conference programme featuring six bookable sessions will highlight the drivers of the current economy and how to navigate the market as it changes. The specific module topics include pharmaceutical manufacturing, commercializing R&D, export strategies and regulations, developing biosimilars, API sourcing, and delivering re-innovated generics. The modules will be structured over day one and day two, and will be presented by high level speakers from the FDA in China, and leading multi-nationals including Pfizer, Boehringer-Ingelheim, Novartis, and GSK China.

As the Chinese government and Ministry of Health (MoH) continue to upgrade protocols in the pharma market and roll out new plans, companies will need to remain flexible to find success. The recent 12th edition of China's Five-year Plan (for years 2011 to 2015) will also help to serve as a guide for companies to strengthen the national drug distribution industry through active support of acquisitions, mergers and reorganizations, as well as the formulation of competitive strategies for the future. The combined China pharma events provide visitors with a unique opportunity to network directly with key decision makers in the Asian pharmaceutical industry through both existing and new contacts. CPhI China, ICSE China and co-located shows provide a one stop location for sourcing quality pharmaceutical products and services at a reasonable price. The events also provide attendees a direct view into the newest market trends and opportunities which results in increased connections and ROI. To learn more about CPhI China, ICSE China and co-located events, or to register to attend, please visit www.cphi-china.com.

Sources:

(1) Manufacturing.net: "China could be 3rd largest pharma market by 2011"

(2) CHEManager Europe: "APIs in China: Pharma Industry Booming in Asia"

Notes for Editors:

Media Enquiries: Company Enquiries:

Impress Labs UBM Live

Global (excl. North America): Richard Kerns Haohao Chen

richard@impresslabs.com Tel: + 31-(0)-20-40-99-593

Tel: + 44-161-728-5880

North America: Beth Willers

beth@impresslabs.com

Tel: +1-503-928-7828

SOURCE　UBM Live